Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does cognitive function improve with quetiapine in comparison to haloperidol?

Dawn I Velligan1, John Newcomer, Joseph Pultz

  • 1Department of Psychiatry, University of Texas Health Science Center at San Antonio, M.S.7792, 7703 Floyd Curl Dr, San Antonio, TX 78229-3900, USA. velligand@uthscsa.edu

Schizophrenia Research
|December 12, 2001
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Cognitive Screening in Community Mental Health Clinics Serving People With Schizophrenia.

Psychiatric services (Washington, D.C.)·2026
Same author

Treatment Patterns and Outcomes from OASIS: A Prospective Observational Study of Long-Acting Injectables in Schizophrenia.

Neuropsychiatric disease and treatment·2025
Same author

Rationale and Challenges for a New Instrument for Remote Measurement of Negative Symptoms.

Schizophrenia bulletin open·2024
Same author

The COMPASS scale for the assessment of individuals with first episode psychotic disorders.

Schizophrenia research·2024
Same author

Mobile Delivery Program to Prevent Relapse and Improve Functioning in Patients With Psychiatric Diseases.

Journal of psychiatric practice·2024
Same author

Current and Emerging Technologies to Address the Placebo Response Challenge in CNS Clinical Trials: Promise, Pitfalls, and Pathways Forward.

Innovations in clinical neuroscience·2024

Quetiapine, an atypical antipsychotic, significantly improved cognitive function, including executive function, attention, and memory, in schizophrenia patients compared to haloperidol. This suggests potential benefits for daily functioning and community outcomes.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia treatment often involves antipsychotics, with varying effects on cognitive function.
  • Atypical antipsychotics are increasingly recognized for potentially improving cognition compared to older agents.

Purpose of the Study:

  • To compare the efficacy of quetiapine versus haloperidol in improving cognitive function in stable schizophrenia outpatients.
  • To assess the impact of these treatments on executive function, memory, and attention.

Main Methods:

  • A randomized, double-blind, multi-site study involving 58 schizophrenia outpatients.
  • Cognitive assessments were conducted at baseline and after 24 weeks of treatment with quetiapine (600 or 300 mg/day) or haloperidol (12 mg/day).
  • Analyses of covariance were used to compare cognitive scores between treatment groups, controlling for baseline function.

Related Experiment Videos

Main Results:

  • Quetiapine (600 mg/day) significantly improved overall cognitive function compared to haloperidol (p<0.02).
  • Specific improvements were observed in executive function (p<0.04), attention (p<0.03), and verbal memory (p<0.02) with higher-dose quetiapine.
  • Observed cognitive benefits were independent of benztropine use, side effects, or symptom changes.

Conclusions:

  • Higher-dose quetiapine (600 mg/day) demonstrates a positive impact on cognitive domains crucial for functional outcomes in schizophrenia.
  • These findings support the use of atypical antipsychotics like quetiapine for enhancing cognitive performance in schizophrenia patients.
  • Improved cognition is linked to better role function and community integration in individuals with schizophrenia.